Septerna, Inc. Increase (Decrease) in Accounts Receivable
Septerna, Inc. (SEPN) reported Increase (Decrease) in Accounts Receivable of $1.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-10
- Septerna, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $1.32M.
- Septerna, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $486.00K, a 515.19% increase year-over-year.
- Septerna, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $1.71M.
- Septerna, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $8.49M, a 84840.00% increase year-over-year.
- Septerna, Inc. increase (decrease) in accounts receivable for fiscal 2025 was $10.19M, a 50825.00% increase from fiscal 2024.
- Septerna, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $20.00K, a 86.75% decline from fiscal 2023.
- Septerna, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $151.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.80M 10-Q · filed 2026-08-10 | $3.52M derived: sum of 3 quarters · filed 2026-08-10 | $12.01M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $486.00K 10-Q · filed 2026-05-11 | $2.20M derived: sum of 2 quarters · filed 2026-05-11 | $10.69M derived: sum of 3 quarters · filed 2026-05-11 | $10.59M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $10.21M derived: sum of 2 quarters · filed 2026-03-09 | $10.11M derived: sum of 3 quarters · filed 2026-08-10 | $10.19M 10-K · filed 2026-03-09 |
| 2025-09-30 | $8.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $8.39M derived: sum of 2 quarters · filed 2026-08-10 | $8.47M 10-Q · filed 2025-11-10 | $8.43M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$99.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$20.00K 10-Q · filed 2026-08-10 | -$60.00K derived: sum of 3 quarters · filed 2026-08-10 | -$50.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $79.00K 10-Q · filed 2026-05-11 | $39.00K derived: sum of 2 quarters · filed 2026-05-11 | $49.00K derived: sum of 3 quarters · filed 2026-05-11 | -$141.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$30.00K derived: sum of 2 quarters · filed 2026-03-09 | -$220.00K derived: sum of 3 quarters · filed 2026-03-09 | $20.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$180.00K derived: sum of 2 quarters · filed 2025-11-10 | $60.00K 10-Q · filed 2025-11-10 | $178.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$190.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $50.00K 10-Q · filed 2025-08-11 | $168.00K derived: sum of 3 quarters · filed 2025-08-11 | |
| 2024-03-31 | $240.00K 10-Q · filed 2025-05-15 | $358.00K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $151.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $33.00K 10-Q · filed 2024-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |